- Trials with a EudraCT protocol (81)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
81 result(s) found for: Glucose uptake.
Displaying page 4 of 5.
EudraCT Number: 2021-000134-34 | Sponsor Protocol Number: TEAM(B115UCS2019) | Start Date*: 2021-05-24 | |||||||||||
Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA | |||||||||||||
Full Title: Time restricted Eating And Metformin (TEAM) in invasive breast cancer (IBC) or ductal carcinoma in situ (DCIS). A randomized, phase IIb, window of opportunity presurgical trial. | |||||||||||||
Medical condition: Luminal (ER+ve and/or PgR+ve >=1%) invasive breast cancer not candidate to neo - adjuvant chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003814-15 | Sponsor Protocol Number: 2012-784 | Start Date*: 2013-03-06 | |||||||||||
Sponsor Name:HOSPICES CIVILS DE LYON | |||||||||||||
Full Title: A multicenter phase II pilot open label study to evaluate the efficacy and safety of BKM120 in the treatment of patients with advanced or metastatic differentiated thyroid cancers | |||||||||||||
Medical condition: Follicular or poorly differentiated cancer refractory to radio iodine | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006280-21 | Sponsor Protocol Number: CORIOLAN | Start Date*: 2012-04-27 | ||||||||||||||||
Sponsor Name:Jules Bordet Institute | ||||||||||||||||||
Full Title: Correlating the tumoral metabolic progression index measured by serial FDG PET-CT and apparent diffusion coefficient measured by MRI to patient's outcome in advance colorectal cancer | ||||||||||||||||||
Medical condition: Advanced colorectal cancer, refractory to all available medications | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-002606-18 | Sponsor Protocol Number: D1600C00001 | Start Date*: 2008-07-10 | ||||||||||||||||
Sponsor Name:Astrazeneca AB | ||||||||||||||||||
Full Title: A Phase I/II, Open Label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Tor Kinase Inhibitor AZD8055 Administered Orally to Patients with A... | ||||||||||||||||||
Medical condition: Advanced solid tumours and lymphomas | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004474-15 | Sponsor Protocol Number: PETFLUTEMETAMOL-FDG/BBRC2015 | Start Date*: 2016-03-14 | ||||||||||||||||
Sponsor Name:BarcelonaBeta Brain Research Center | ||||||||||||||||||
Full Title: Characterization of cerebral amyloid deposition with 18F-Flutemetamol PET and of glucose metabolism with 18F-FDG PET in individuals enrolled in the ALFA project | ||||||||||||||||||
Medical condition: Study to understand factors related with the preclinical stages of Alzheimer's Disease and investigate markers that predict its progression. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003296-34 | Sponsor Protocol Number: OTX116505 | Start Date*: 2014-01-29 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Single Blind, Randomised, Placebo Controlled, Repeat Dose, Dose Escalating Study Investigating Safety, Tolerability Pharmacokinetics, Pharmacodynamics and the Beta-Cell Preserving Effect of Oteli... | |||||||||||||
Medical condition: NOT1DM is an autoimmune disease. This means that the immune system, the part of the body which usually helps to fight infections, mistakenly attacks cells that produce insulin in the body. Insulin ... | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004790-18 | Sponsor Protocol Number: 2008DM05 | Start Date*: 2008-10-21 | |||||||||||
Sponsor Name:University of Dundee | |||||||||||||
Full Title: Response to Oral Agents in Diabetes (ROAD) Pilot Study | |||||||||||||
Medical condition: Type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005338-35 | Sponsor Protocol Number: PM1111138 | Start Date*: 2009-04-01 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A double-blind, placebo-controlled, parallel group study to evaluate the effects of two regimens of GW856553, over a period of 3 months, on in-vivo macrophage activity, as assessed by FDG-PET/CT im... | |||||||||||||
Medical condition: GW-856553 is under development as a potential anti-atherosclerosis agent for reduction of major cardiovascular events in high risk patient populations. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005140-18 | Sponsor Protocol Number: RAME-01 | Start Date*: 2015-11-12 | |||||||||||
Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA | |||||||||||||
Full Title: Diagnostic and clinical value of fused 64CuCl2-PET/MRI in prostate cancer relapse. Comparison with multiparametric MRI (mMRI) and 18F-Choline-PET/MRI | |||||||||||||
Medical condition: Prostate cancer patients who showed biochemical relapse after surgery or first-line treatment with radiotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004830-25 | Sponsor Protocol Number: KIT | Start Date*: 2015-09-01 | |||||||||||
Sponsor Name:Oslo University Hospital | |||||||||||||
Full Title: Kidney Cancer Integrated Therapy (KIT) - Personalized integrated therapy for patients with advanced kidney cancer | |||||||||||||
Medical condition: Personalized integrated therapy for patients with advanced kidney cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001564-26 | Sponsor Protocol Number: TRIMETA | Start Date*: 2022-04-15 | |||||||||||
Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO | |||||||||||||
Full Title: Evaluation of the cardioprotective metabolic effect of trimetazidine in patients with myocardial ischaemia | |||||||||||||
Medical condition: Patients with clinical diagnosis of Inducible Myocardial Ischemia (exercise stress test positive for electrocardiographic criteria and /or symptoms) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003511-11 | Sponsor Protocol Number: D5881C00006 | Start Date*: 2015-01-14 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Two-part, Open-label, Randomised, Crossover, Multicentre, Phase II Study to Investigate the Presence of Pancreatic Exocrine Insufficiency (PEI) in Patients with Type 2 Diabetes Mellitus, and to I... | |||||||||||||
Medical condition: Type 2 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) SE (Completed) DK (Completed) HU (Completed) LV (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000616-28 | Sponsor Protocol Number: OCTO_038 | Start Date*: 2013-08-22 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: Phase II trial of Linsitinib (anti-IGFR/IR) in patients with relapsed and/or refractory Ewing Sarcoma | |||||||||||||
Medical condition: Relapsed and/or refractory Ewing sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002866-11 | Sponsor Protocol Number: TRx-237-015 | Start Date*: 2013-01-23 | |||||||||||
Sponsor Name:TauRx Therapeutics Ltd | |||||||||||||
Full Title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's Disease | |||||||||||||
Medical condition: Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005995-14 | Sponsor Protocol Number: 3133K1-3001-WW(B2521002) | Start Date*: 2009-05-29 | |||||||||||
Sponsor Name:Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disea... | |||||||||||||
Medical condition: Alzheimer Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IE (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) FR (Completed) FI (Prematurely Ended) SE (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005994-79 | Sponsor Protocol Number: 3133K1-3000-WW | Start Date*: 2008-05-13 | |||||||||||
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development | |||||||||||||
Full Title: Ensayo de fase III, multicéntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, sobre la eficacia y la seguridad del bapineuzumab (AAB-001, ELN115727) en pacientes co... | |||||||||||||
Medical condition: Enfermedad de Alzheimer Alzheimer Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) IE (Prematurely Ended) GB (Prematurely Ended) BE (Completed) DE (Prematurely Ended) FR (Completed) FI (Prematurely Ended) SE (Prematurely Ended) IT (Prematurely Ended) SK (Completed) PT (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000307-17 | Sponsor Protocol Number: DIAN-TU-001 | Start Date*: 2014-01-08 |
Sponsor Name:Washington University in St. Louis | ||
Full Title: A Phase II/III randomized, double-blind, placebo-controlled, cognitive endpoint, multicenter study of potential disease modifying therapies in individuals at risk for and with dominantly inherited ... | ||
Medical condition: Dominantly Inherited Alzheimer Disease (DIAD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) IT (Trial now transitioned) ES (Temporarily Halted) DE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003558-17 | Sponsor Protocol Number: TRx-237-039 | Start Date*: 2018-02-25 | |||||||||||
Sponsor Name:TauRx Therapeutics Ltd | |||||||||||||
Full Title: Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of Hydromethylthionine Mesylate (LMTM) Monotherapy in Subjects with Alzheimer's Disease Followed by a 12... | |||||||||||||
Medical condition: Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) PL (Completed) ES (Ongoing) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004455-32 | Sponsor Protocol Number: IMB101-006 | Start Date*: 2021-02-16 |
Sponsor Name:Imbria Pharmaceuticals, Inc. | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Patients with Angina due to Coronary Syndrome | ||
Medical condition: Stable coronary artery disease (CAD) /Chronic coronary syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) FI (Completed) DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000690-36 | Sponsor Protocol Number: TED14856 | Start Date*: 2018-12-17 | |||||||||||
Sponsor Name:SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT | |||||||||||||
Full Title: A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy, then in Combination with Palbociclib in Postmenopausal... | |||||||||||||
Medical condition: Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Trial now transitioned) PT (Prematurely Ended) ES (Prematurely Ended) CZ (Completed) PL (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
